好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Randomized Trial of Telemedicine for Migraine Management
Headache
P4 - Poster Session 4 (5:30 PM-6:30 PM)
13-001

To determine whether telemedicine was equivalent to in-office visits for follow-up migraine care in a tertiary headache center

Telemedicine offers the capability of increasing access to care by providing expertise in headache medicine to patients in diverse locations and circumstances.  Migraine care lends itself well to this technology, as there is generally no need for a physical examination after the initial office visit.

 

After their initial visit, 45 patients were randomized to receive their follow-up care for one year (5 scheduled visits) by the same neurologist either in the office or using telemedicine.  Data were collected after each visit on headache disability (MIDAS), travel time and distance from the office, time missed from work, convenience of visits, study adherence, wait times, volume of communication between visits, hospitalizations and emergency department encounters for headache, perceptions of telemedicine and patient satisfaction.  Willing participants were interviewed by telephone after the completion of the study about their experience.  Data from enrollees completing at least one follow-up visit were included in the analysis.

30 participants completed all visits.  Improvement in migraine-related disability, number of headache days, average severity of migraines, communication with the office between visits, perceived effectiveness of care and satisfaction with the provider were similar in the in-office and telemedicine groups.  The average time for a visit (including travel) was 194 minutes for the in-office group and 37 minutes in the telemedicine group (p<0.001).  Face-to-face contact duration with the neurologist was longer during in-office visits.  Overall satisfaction was higher in the telemedicine group, largely attributable to decreased travel time and less need to miss work. 

In this cohort of patients with severe migraine-related telemedicine was an effective alternative to in-office visits for follow-up migraine care.  Headache outcomes using telemedicine were equivalent to in-office visits with higher rates of patient satisfaction using telemedicine. 

Authors/Disclosures
Deborah I. Friedman, MD, MPH, FAAN
PRESENTER
Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Friedman has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Pfizer. Dr. Friedman has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Axsome. Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amneal. Dr. Friedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie. Dr. Friedman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Axsone. Dr. Friedman has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Pfizer. Dr. Friedman has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink Neurology . Dr. Friedman has a non-compensated relationship as a Program Co-Chair, Scottsdale Headache Symposium with American Headache Society that is relevant to AAN interests or activities. Dr. Friedman has a non-compensated relationship as a Medical Advisor with Spinal CSF Leak Foundation that is relevant to AAN interests or activities. Dr. Friedman has a non-compensated relationship as a President-elect, Board of Directors with Southern Headache Society that is relevant to AAN interests or activities.
No disclosure on file
No disclosure on file